Setting the Stage
The Diabetes Technology Meeting 2024 is one of the most anticipated events in diabetes care, bringing together researchers, healthcare professionals, and innovators to showcase the latest breakthroughs. At this year’s meeting, Orange Biomed unveiled new approaches to tackling one of the most pressing issues in diabetes management: A1C testing gaps. By focusing on accuracy and equity, Orange Biomed aims to make a significant impact on diabetes care, particularly for underserved populations.
The Current Landscape of A1C Testing
A1C testing plays a crucial role in monitoring diabetes, providing an indicator of average blood sugar levels over several months. While A1C is a well-established and standardized test supported by extensive clinical studies, it’s important to recognize that portable A1C tests can deliver differing levels of accuracy for diverse patient populations.
Research shows that A1C tests can generate false results for nonwhite patient populations with higher levels of hemoglobin variants. These inaccuracies, particularly in portable A1C testing, could lead to inadequate care and disparities in diabetes management outcomes, as these tests have historically struggled to address the interference caused by hemoglobin variants.
Innovations to Be Unveiled by Orange Biomed
At the forefront of addressing these challenges is Orange Biomed’s OBM rapid A1c, a microfluidic-based A1C test set to redefine accuracy standards. This test provides lab-level results in just five minutes using a single drop of blood. The innovation ensures consistent results for individuals regardless of hemoglobin variants, thereby contributing to more equitable healthcare.
The OBM rapid A1c is currently under development, with FDA clearance expected in 2025. This makes the technology highly anticipated, promising to offer a more reliable solution to diabetes management in diverse communities.
Orange Biomed at the Diabetes Technology Meeting 2024
Orange Biomed is actively participating in various segments of the meeting:
Startup Showcase: On Wednesday, October 16, from 5-7pm, Orange Biomed presented the OBM rapid A1c at the Startup Showcase. Attendees gained an in-depth look at how this innovative product works.
Poster Presentation: On Tuesday, October 15, from 4:30-6:30pm, Orange Biomed presented a poster outlining the critical benefits and innovations behind the OBM rapid A1c technology.
Panel Discussions: Our experts are also participating in panel discussions focusing on current issues in A1C testing and solutions for improving healthcare equity.
Broader Innovations in A1C Testing and Diabetes Care
In addition to Orange Biomed’s showcase, the Diabetes Technology Meeting covers broader topics related to diabetes management, including:
- Continuous Glucose Monitoring (CGM) advancements, which offers real-time data to patients and healthcare providers.
- Integration of AI technology to analyze data from A1C and CGM devices, helping to create personalized treatment plans.
Attendees will also learn about innovations from other companies and researchers working on complementary solutions, all of which contribute to the common goal of improving diabetes care.
How Orange Biomed’s Innovations Are Shaping the Future
The OBM rapid A1c promises to create a transformative change in diabetes care by ensuring accuracy and accessibility. With a focus on eliminating disparities in testing accuracy, Orange Biomed is committed to making diabetes management fair and effective for all patients, regardless of their background.
The use of microfluidic technology allows for precise measurement, and the compact design makes it ideal for both clinics and at-home testing, giving patients and healthcare professionals a reliable way to monitor and manage diabetes.
Collaboration Opportunities with Orange Biomed
Orange Biomed is seeking partnerships with healthcare providers, research institutions, and industry leaders who share their vision for equitable diabetes care. We invite interested parties to schedule a meeting during the Diabetes Technology Meeting or contact us to learn more about our innovative work.
Book a Meeting or Visit Our Booth at the event to discuss collaboration opportunities and learn how you can be part of this transformation in diabetes care.
Conclusion
The Diabetes Technology Meeting 2024 is a turning point for the future of A1C testing and diabetes management. By addressing the current gaps in A1C testing accuracy, Orange Biomed aims to create a positive and lasting impact. Thank you to everyone who has joined us at the event to discover how our innovations can improve diabetes care for diverse populations and be part of this exciting journey.
